One of the main goals of TGEN's Molecular Genetics Laboratory is to utilize siRNA technology to identify putative genes as part of drug discovery, which may play a role in the development of therapeutics for cancer and other genetic disorders. The lab also provides services for the validation of high-throughput RNAi screening and gene expression profiling. For this the group uses real-time quantitative PCR (qRT-PCR).
During this week's GEN podcast, Dr. Tuzmen talks about why qRT-PCR is the method of choice for validation of RNAi knockdowns. Regarding his research team’s application of global RNAi phenotype analysis for cancer drug target identification and the validation of drug targets by qRT-PCR., Dr. Tuzmen also explains why global RNAi profiling was used in this work and discusses what his team discovered. He also identifies the range of areas in cancer research where global RNAi phenotype analysis and use of qRT-PCR can be applied.
Listen to the podcast then return to the blog and give your thoughts on the following question:
Where do you see the most promising applications of Quantitative Real Time PCR in cancer research?